文献速递心脑血管急症重症综合管理与镇静镇痛

中性粒细胞胞外诱捕网与动脉瘤性蛛网膜下腔出血后的迟发性脑缺血

Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · Crit Care Explor · 2022-05-17
一句话结论动脉瘤性蛛网膜下腔出血患者入院时血清MPO-DNA复合物均检出,DCI患者从入院至第4天显著下降,可能作为DCI早期标志物。

本研究为前瞻性观察性单中心研究的事后分析,纳入2018年7月至2020年9月连续收治的100例自发性蛛网膜下腔出血患者,其中78例确诊动脉瘤性蛛网膜下腔出血,29例(37%)发生迟发性脑缺血(DCI,定义为脑CT新发梗死)。检测入院时和第4天血清MPO-DNA复合物浓度,所有样本均可检出;中位水平从入院时33 ng/mL(IQR 18-43)降至第4天22 ng/mL(IQR 11-31)(非配对检验 p=0.015)。DCI患者从入院至第4天MPO-DNA水平显著下降(配对检验 p=0.036),无DCI者未下降(p=0.17);临床血管痉挛患者亦显著下降(p=0.006),无血管痉挛者未下降(p=0.47)。作者认为MPO-DNA水平显著下降可能作为DCI的早期标志物,其诊断价值和治疗靶点作用需进一步探索。

要点

  • 78例确诊aSAH患者中29例(37%)发生DCI,DCI定义为脑CT新发梗死。
  • 所有aSAH患者血清均检出MPO-DNA复合物,中位水平入院时33 ng/mL(IQR 18-43),第4天22 ng/mL(IQR 11-31)(非配对检验 p=0.015)。
  • DCI患者从入院至第4天MPO-DNA水平显著下降(配对检验 p=0.036),无DCI者未显著下降(p=0.17)。
  • 临床血管痉挛患者从入院至第4天MPO-DNA水平显著下降(p=0.006),无临床血管痉挛者未显著下降(p=0.47)。
  • 作者认为MPO-DNA水平显著下降可能作为DCI的早期标志物,其诊断潜力和治疗靶点作用需进一步探索。

适用人群与场景

  • 2018年7月至2020年9月连续收治于三级医疗神经科学ICU的动脉瘤性蛛网膜下腔出血患者。
  • 共100例自发性蛛网膜下腔出血患者纳入,其中78例确诊动脉瘤性蛛网膜下腔出血;平均年龄59岁(标准差±13岁),55%为女性。

诊断标准与关键阈值

  • DCI定义为脑CT新发梗死。
  • 临床血管痉挛为临床参数与经颅多普勒参数组成的复合终点。

研究设计与关键结果

  • 研究设计:前瞻性观察性单中心研究的事后分析,新检测连续动脉瘤性蛛网膜下腔出血患者血清生物标志物。
  • 样本量:100例自发性蛛网膜下腔出血患者,其中78例确诊动脉瘤性蛛网膜下腔出血,29例(37%)发生DCI。
  • 主要终点:所有样本均检出MPO-DNA复合物;中位MPO-DNA水平入院时33 ng/mL(IQR 18-43),第4天22 ng/mL(IQR 11-31),非配对检验 p=0.015。
  • DCI患者从入院至第4天MPO-DNA水平显著下降(配对检验 p=0.036),无DCI者未显著下降(p=0.17)。
  • 临床血管痉挛患者从入院至第4天MPO-DNA水平显著下降(p=0.006),无临床血管痉挛者未显著下降(p=0.47)。

证据类型、等级与局限

  • 证据类型:前瞻性观察性单中心研究的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为MPO-DNA水平显著下降可能作为DCI的早期标志物;其诊断潜力和作为治疗靶点的作用应进一步探索。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Myeloperoxidase (MPO)-DNA complexes, biomarkers of neutrophil extracellular traps (NETs), have been associated with arterial and venous thrombosis. Their role in aneurysmal subarachnoid hemorrhage (aSAH) is unknown.

OBJECTIVES: To assess whether serum MPO-DNA complexes are present in patients with aSAH and whether they are associated with delayed cerebral ischemia (DCI).

DESIGN SETTING AND PARTICIPANTS: Post-hoc analysis of a prospective, observational single-center study, with de novo serum biomarker measurements in consecutive patients with aSAH between July 2018 and September 2020, admitted to a tertiary care neuroscience ICU.

MAIN OUTCOMES AND MEASURES: We analyzed serum obtained at admission and hospital day 4 for concentrations of MPO-DNA complexes. The primary outcome was DCI, defined as new infarction on brain CT. The secondary outcome was clinical vasospasm, a composite of clinical and transcranial Doppler parameters. We used Wilcoxon signed-rank-test to assess for differences between paired measures.

RESULTS: Among 100 patients with spontaneous subarachnoid hemorrhage, mean age 59 years (sd ± 13 yr), 55% women, 78 had confirmed aSAH. Among these, 29 (37%) developed DCI. MPO-DNA complexes were detected in all samples. The median MPO-DNA level was 33 ng/mL (interquartile range [IQR], 18-43 ng/mL) at admission, and 22 ng/mL (IQR, 11-31 ng/mL) on day 4 (unpaired test; p = 0.015). We found a significant reduction in MPO-DNA levels from admission to day 4 in patients with DCI (paired test; p = 0.036) but not in those without DCI (p = 0.17). There was a similar reduction in MPO-DNA levels between admission and day 4 in patients with (p = 0.006) but not in those without clinical vasospasm (p = 0.47).

CONCLUSIONS AND RELEVANCE: This is the first study to detect the NET biomarkers MPO-DNA complexes in peripheral serum of patients with aSAH and to associate them with DCI. A pronounced reduction in MPO-DNA levels might serve as an early marker of DCI. This diagnostic potential of MPO-DNA complexes and their role as potential therapeutic targets in aSAH should be explored further.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Witsch J, Spalart V, Martinod K, et al. Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage. Crit Care Explor. 2022. PMID: 35620772. doi:10.1097/CCE.0000000000000692

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。